Research programme: embryonic stem cell therapies - Asterias Biotherapeutics

Drug Profile

Research programme: embryonic stem cell therapies - Asterias Biotherapeutics

Alternative Names: CHND-1; GRNCHND1

Latest Information Update: 20 Aug 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Geron Corporation
  • Developer Asterias Biotherapeutics; Geron Corporation; University Campus Suffolk; University of Edinburgh
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Fracture; Liver failure; Osteoarthritis; Osteoporosis

Most Recent Events

  • 10 Aug 2015 BioTime has a patent protection for the manufacturing method of cartilage cells
  • 26 Jan 2015 BioTime receives patent allowance for Stem cell technologies in Europe, Canada, Singapore and Israel
  • 01 Oct 2013 Preclinical trials in Fracture in USA (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top